PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
In IMpower010, Tecentriq significantly reduced the risk of death or disease recurrence in patients with stage II to IIIA tumors, particularly in those with PD-L1 expression.
The Phase III trial explored two combinations, Opdivo plus Yervoy and Opdivo plus chemo, in esophageal cancer and stratified patients based on PD-L1 expression.
Biodesix, Addario Lung Cancer Institute Enroll First Patient in NSCLC Biomarker Study
Through the BEACON-Lung study, investigators will use Biodesix's serum-based test to identify predictive biomarkers of immunotherapy response beyond PD-L1.
CHMP Recommends Merck's Keytruda Plus Chemo for Certain Esophageal, Gastroesophageal Cancers
The EMA committee recommended approval for pembrolizumab plus chemo as first-line treatment for patients whose tumors express a PD-L1 CPS of 10 or more.
EMA's CHMP Issues Positive Opinion on Regeneron, Sanofi's Libtayo in NSCLC
The committee recommended approval for the anti-PD-1 drug in first-line NSCLC patients who have PD-L1 expression in at least 50 percent of tumor cells.